Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 10/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | HTR1E | P28566 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211442 | 0.84 | HTR1D (0.46) | CDK7CDK9HTR1DSLC6A4HTR1E | |
| SCHEMBL3661903 | 0.83 | HTR1D (0.44) | NOS3NOS1SLC6A2CDK7CDK9 | |
| SCHEMBL3227327 | 0.81 | SLC6A4 (0.66) | NOS3NOS1SLC6A2CDK7CDK9 | |
| SCHEMBL7951141 | 0.80 | HTR1D (0.41) | CDK7CDK9HTR1DHTR1EHTR1A | |
| SCHEMBL3217678 | 0.78 | CDK7 (0.45) | CDK7CDK9HTR1DHTR1EHTR1A | |
| SCHEMBL3216107 | 0.76 | CDK9 (0.39) | CDK7CDK9HTR1DSLC6A4 | |
| SCHEMBL3206033 | 0.76 | CDK9 (0.39) | CDK7CDK9HTR1DSLC6A4 | |
| SCHEMBL3214861 | 0.76 | JAK3 (0.39) | CDK7CDK9HTR1DHTR1EHTR1A | |
| SCHEMBL3653965 | 0.74 | HTR1D (0.41) | CDK7CDK9HTR1DSLC6A4HTR1E | |
| SCHEMBL3216008 | 0.74 | JAK2 (0.44) | CDK7CDK9HTR1DHTR1EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010024980-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | NOS3 1141/4885NOS1 1762/4885SLC6A2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.